We at Med Ad News don’t claim to know all the questions. So we challenged our contributors to come up with their own questions and answer them.
Tag Archive for: GLP-1 drugs
Two Florida courts last week ruled in Novo Nordisk’s favor in its legal battle against wellness clinics and compounding pharmacies for marketing counterfeit or compounded versions of its popular weight-loss drug semaglutide.
The European Medicines Agency is investigating the potential impacts that Novo Holdings’ $16.5 billion acquisition of contract manufacturing giant Catalent will have on drug supply, according to reporting Wednesday by Reuters.
The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly’s (LLY.N) highly-effective Zepbound, but Amgen is taking a unique approach.
Stringent regulation, manufacturing costs and absence of price control contribute to high GLP-1 agonist costs in the U.S. Patients could go to other countries for cheaper treatment.
The persistent shortage of genuine glucagon-like peptide 1 receptor agonist products has led to an increase in fake versions, the World Health Organization warned on Monday.
Patients on Eli Lilly’s weight-loss drug Zepbound substantially regained weight nearly a year after stopping treatment, according to full results of a study published on Monday.
The safety panel reviewed data from Novo’s popular diabetes drug Ozempic and weight loss treatment Wegovy, which contain the same active ingredient, semaglutide.
The company stated that it has capacity to fill syringes to serve makers of highly popular new weight-loss drugs in a class known as GLP-1, though it does not produce the active ingredient in those drugs.
UnitedHealth Group said on Friday it will focus on finding a way to make GLP-1 drugs, used for the treatment of weight loss and diabetes, more affordable for its customers.